Koers Pain Therapeutics, Inc. Nasdaq
Aandelen
US69562K5065
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | 150 mln. 139 mln. | Marktkapitalisatie | 971 mln. 900 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -96 mln. -88,99 mln. | Nettowinst (verlies) 2025 * | - 0 | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 6,47 x |
K/w-verhouding 2024 * |
-9,43
x | K/w-verhouding 2025 * |
-42,6
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,66% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Remi Barbier
CEO | Chief Executive Officer | 64 | 01-05-98 |
Eric Schoen
DFI | Director of Finance/CFO | 55 | 01-10-18 |
James Kupiec
CTO | Chief Tech/Sci/R&D Officer | - | 04-01-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Remi Barbier
CEO | Chief Executive Officer | 64 | 01-05-98 |
Robert Gussin
BRD | Director/Board Member | 86 | 01-03-03 |
Patrick Scannon
BRD | Director/Board Member | 76 | 07-12-07 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+5,27% | 109 mld. | |
+11,27% | 105 mld. | |
-0,38% | 22,25 mld. | |
-12,08% | 22,09 mld. | |
-7,66% | 18,68 mld. | |
-36,52% | 17,58 mld. | |
-10,36% | 16,85 mld. | |
+2,87% | 13,76 mld. | |
+35,80% | 12,46 mld. |